Correlation Between Short- and Mid-Term Hemoglobin A1c and Glycemic Control Determined by Continuous Glucose Monitoring

Jen-Hung Huang  
Taipei Medical University

Yung-Kuo Lin  
Taipei Medical University

Ting-Wei Lee  
Taipei Medical University

Han-Wen Liu  
Taipei Municipal Wan-Fang Hospital

Yu-Mei Chien  
Taipei Municipal Wan-Fang Hospital

Yu-Chun Hsueh  
Taipei Municipal Wan-Fang Hospital

Ting-I Lee  
agleems29@gmail.com  
Taipei Medical University  
https://orcid.org/0000-0002-4883-0199

Yi-Jen Chen  
Taipei Medical University

Research Article

Keywords: diabetes mellitus, continuous glucose monitoring, Hemoglobin A1c

Posted Date: June 29th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-631619/v1

License: ☺ ➔ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Glucose monitoring is vital for glycemic control in patients with diabetes mellitus (DM). Continuous glucose monitoring (CGM) measures whole-day glucose levels. Hemoglobin A1c (HbA1c) is a vital outcome predictor in patients with DM.

Methods: This study investigated the relationship between HbA1c and CGM, which remained unclear hitherto. Data of patients with DM (n = 91) who received CGM and HbA1c testing (1-3 months before and after CGM) were retrospectively analyzed. Diurnal and nocturnal glucose, highest CGM data (10%, 25%, and 50%), mean amplitude of glycemic excursions (MAGE), percent coefficient of variation (%CV), and continuous overlapping net glycemic action were compared with HbA1c values before and after CGM.

Results: The CGM results were significantly correlated with HbA1c values measured 1 (r = 0.69) and 2 (r = 0.39) months after CGM and 1 month (r = 0.35) before CGM. However, glucose levels recorded in CGM did not correlate with the HbA1c values 3 months after and 2-3 months before CGM. MAGE and %CV were strongly correlated with HbA1c values 1 and 2 months after CGM, respectively. Diurnal blood glucose levels were significantly correlated with HbA1c values 1-2 months before and 1 month after CGM. The nocturnal blood glucose levels were significantly correlated with HbA1c values 1-3 months before and 1-2 months after CGM.

Conclusions: CGM can predict HbA1c values within 1 month after CGM in patients with DM.

Introduction

Clinical investigations have illustrated the correlation of hemoglobin A1c (HbA1c) values with both microvascular and macrovascular complications in patients with diabetes mellitus (DM) [1, 2]. Strict glycemic treatment plays a crucial role in preventing the development and progression of long-term complications associated with DM. HbA1c values are associated with blood glucose levels over the lifetime of red blood cells (approximately 120 days) and is the current gold standard for clinical monitoring of glycemic control in DM [3, 4]. A study reported a strong correlation between HbA1c values and mean blood glucose levels by using the 7-point blood glucose profiles [5]. Accordingly, HbA1c values were hypothesized to represent relatively long-term glycemic status in patients with DM [6]. The International Diabetes Federation and American Diabetes Association have reported that the HbA1c value < 7.0% is a target for improving DM control [7, 8]. However, intensive treatment of DM is accompanied by hypoglycemia. Severe hypoglycemia may be a critical cause of morbidity. Furthermore, the optimal strategy for monitoring HbA1c values in patients with DM is not well established.

Glucose monitoring is a crucial aspect of DM control. The current accessibility of continuous glucose monitoring (CGM) systems is considered a valuable development in the management of DM. CGM enables the recording of various glucose data, including glucose excursions, patterns, and trends and timepoints of the associated changes, in an attempt to optimize glycemic control [9, 10]. Recent meta-analyses have revealed that CGM system-based blood glucose monitoring is more effective for glycemic control in patients of type 1 and 2 DM than self-monitoring of blood glucose [11–13]. However, approved CGM systems demonstrate suboptimal accuracy [14–16]. In this study, we investigated the relationship between CGM system results and HbA1c values and evaluated which timepoints of HbA1c values were related to CGM as well as CGM parameters correlated with glycemic control in patients with DM.

Materials And Methods

Study Population

We retrospectively analyzed data of patients with DM who received CGM. CGM was performed using iPro2 (Medtronic, Northridge, CA, USA) for 5 days and 24-hour CGM data were extracted from the first or second day of glucose monitoring. In total, 91 patients with DM received CGM, of which 27 (30%) had type 1 DM and 64 (70%) had type 2 DM. The age, body height and weight, comorbidity, and history of medications of each participant were recorded. HbA1c values were measured using Sebia Capillarys 2 Flex Piercing (Sebia Electrophoresis, France). The HbA1c data were collected from 3 months before and 3 months after CGM. Very high (> 400mg/dL) and very low (< 40mg/dL) blood glucose levels recorded through CGM, and patients with anemia were excluded. The blood glucose levels recorded from 0600 to 2200 represented diurnal blood glucose, and those from 2200 to 0600 represented nocturnal blood glucose levels. The whole-day, diurnal, and nocturnal glucose levels during CGM were calculated based on the average of the highest 10% (CGM_H10%), 25% (CGM_H25%), and 50% (CGM_H50%) or all data (CGM_100%). The mean amplitude of glycemic excursions (MAGE), classical standard deviation (SD), continuous overlapping net glycemic action (CONGA), and calculated coefficient of variation (CV) were calculated using Glycemic Variability Analyzer Program 1.1 (MATLAB 2010b; MathWorks, USA).

Statistical Analysis
Continuous variables are expressed as mean ± SD and were compared using Student t test. Categorical variables were reported as frequencies and compared using the χ² or Fisher exact test if at least one cell had an expected cell count of < 5. A two-tailed P < 0.05 was considered statistically significant. A linear correlation was used to correlate the measured parameters. All statistical analyses were performed on SigmaPlot (version 12.3).

Results

Of the 91 patients with DM who received CGM, 9 patients with markedly elevated or very low blood glucose levels were excluded; of the remaining patients, 23 and 59 were diagnosed as having type 1 and 2 DM, respectively (Table 1). Patients with type 1 DM were younger and taller than patients with type 2 DM. Table 2 illustrates that the blood glucose levels (CGM$_{100%}$) measured through CGM were significantly correlated with HbA1c values measured 1 (r = 0.69) and 2 (r = 0.39) months after CGM and 1–3 months (r = 0.35) before CGM. The HbA1c values 1 month after CGM was significantly correlated with the highest 10% (CGM$_{H10%}$, r = 0.72), 25% (CGM$_{H25%}$, r = 0.74), and 50% (CGM$_{H50%}$, r = 0.73) measured from CGM. The CGM$_{H50%}$ of blood glucose levels was significant with HbA1c values 3 months before and 1 month after CGM, but not with HbA1c values 1–2 months before and 2–3 months after CGM. However, the CGM$_{H10%}$ and CGM$_{H25%}$ of blood glucose levels during CGM did not correspond to HbA1c values measured 1–3 months before and 2–3 months after CGM. The diurnal blood glucose levels were significantly correlated with HbA1c values 1 and 2 months before and 1 month after CGM. The nocturnal blood glucose levels were significantly correlated with HbA1c values 1–3 months before and 1–2 months after CGM.

Table 3 displays the glycemic variation of patients with type 1 and 2 DM over 3 months before and 3 months after CGM. The mean, SD, MAGE, CONGA, and CV values were calculated for each patient. Table 4 displays the relationship between HbA1c and glycemic variation, including SD, percent CV (%CV), MAGE, and CONGA. Overall, the SD and MAGE were significantly correlated to HbA1c values in the next 1 month, and the %CV was significantly correlated to HbA1c values 2 months after CGM. The %CV was significantly correlated with the HbA1c values 2 months after CGM in patients with type 1 DM. In patients with type 2 DM, the SD and MAGE were significantly correlated to HbA1c values 1 month after CGM and the %CV was significantly correlated with HbA1c values 2 months after CGM.

Discussion

The goal of DM treatment is to prevent chronic complications [17, 18]. Glucose monitoring is crucial in DM control. HbA1c assay is recommended as the optimal approach to monitoring DM glycemic control [19] and is used globally as the basis of adjustment in treatment guidelines [20–22]. A study reported a strong correlation between HbA1c values and mean blood glucose levels using 7-point blood glucose profiles [23]. However, the optimal strategy for monitoring HbA1c values was not clear because the relationship of DM control and HbA1c values in intensive glucose monitoring is not well established. CGM could provide more blood glucose data and contribute to the improvements in DM management, as demonstrated by the significant lowering of HbA1c values in patients with DM [24–27]. However, studies have noted strong correlations between CGM interstitial glucose and venous plasma or capillary glucose levels [28–30]. Studies have reported a less than acceptable correlation between CGM interstitial glucose results and venous plasma or capillary glucose levels [31, 32]. In this study, we determined that CGM may correlate well with HbA1c values over 3 months before and 3 months after CGM. The CGM was most closely related to HbA1c values in the next month after CGM when measured based on the interstitial glucose levels every 5 min for 5 days.

Sharp and Rainbow have demonstrated that CGM was strongly correlated with HbA1c values at the time of insertion [33]. Saladri et al also identified a correlation between the area under the glucose curve of CGM and HbA1c values in patients with type 1 DM [34]. Furthermore, Nathan et al. extensively analyzed CGM and identified a strong correlation between the mean glucose measured by CGM and HbA1c values [30]. Glucose variability may be a factor in DM complications [35]. An acute increase in blood glucose can produce significant alterations in normal homeostasis, leading to endothelial dysfunction and inflammation, among other effects [36]. A study indicated that MAGE was not correlated to HbA1c values [37]. In this study, we determined that MAGE was poorly associated with HbA1c values at several timepoints but was significantly correlated with the HbA1c values 1 month after CGM, particularly in patients with type 2 DM. Furthermore, CGM is vital in improving glucose variability to achieve strict glycemic control.

Several factors may alter the relationship between the mean blood glucose levels and HbA1c values. For instance, variable red cell turnover may be affected by hyperglycemia [38]. Moreover, glycation rates may differ among individuals at the same mean blood glucose levels [39]. Notably, the negative correlation between measured mean glucose levels and HbA1c values 3 months after CGM may also suggest an improvement in the mean glucose levels after the intervention based on the CGM results.

In conclusion, the association of CGM results with HbA1c values 1 month after monitoring was positive. Furthermore, CGM could record glucose variability and is a reliable tool to assess glycemic state and improve DM management.
Limitations
The limitations of this study should be considered. First, this study was single-center and the sample size was small. Larger studies using comparable assessment of chronic glycemia will be needed to determine whether differential glycation exists. Second, the CGM data were retrospectively collected from the medical history, and HbA1c data were not integrated.

Declarations

Acknowledgments
This study was financed by the Ministry of Science and Technology (MOST 107-2314-B-038-097-MY2, MOST 107-2314-B-038-099-MY3, MOST 108-2314-B-038-042 and MOST 109-2314-B038-098) and from Taipei Medical University-Wan Fang Hospital (105swf02, 106-eva-06 and 107-wf-eva-13).

Funding
The present work was supported by grants from the Ministry of Science and Technology (MOST 107-2314-B-038-097-MY2, MOST 107-2314-B-038-099-MY3, MOST 108-2314-B-038-042 and MOST 109-2314-B038-098) and from Taipei Medical University-Wan Fang Hospital (105swf02, 106-eva-06 and 107-wf-eva-13).

Data Availability
The data used to support the findings of this study are available from the corresponding authors upon request.

Declarations

Authors' contributions
Conception or design: T.I.L, Y.J.C.
Acquisition, analysis, or interpretation of data: J.H.H., Y.K.L., T.W.L., H.W.L.
Drafting the work or revising: J.H.H., Y.K.L., T.W.L., H.W.L., Y.M.C., Y.C.H.
Final approval of the manuscript: J.H.H., Y.K.L., T.W.L., H.W.L., Y.M.C., Y.C.H., T.I.L, Y.J.C.

Ethics approval and consent to participate
This retrospective study was approved by the Taipei Medical University-Joint Institutional Review Board (TMU-JIRB; approval number:N202001006). The requirement for obtaining informed consent was waived by the TMU-JIRB due to the retrospective nature of the investigation.

Consent for publication
Not applicable.

Competing interests
This paper does not have a conflict of interest.

References
1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuith S, Lachin J, Cleary P, Crofford Q, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
3. Nathan DM, Singer DE, Huxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341–346.
4. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 1993;16:1313–1314.

5. Rohlfing, CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the Relationship Between Plasma Glucose and HbA1c. Diabetes Care 2002;25:275–278.

6. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med 1976;295:417–420.

7. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014;104:1–52.

8. American Diabetes Association. 6. Glycemic Targets. Diabetes Care 2017;40:S48-S56.

9. Buckingham, B. Clinical overview of continuous glucose monitoring. J Diabetes Sci Technol 2008;2:300–306.

10. Blevins, TC. Professional continuous glucose monitoring in clinical practice 2010. J Diabetes Sci Technol 2010;4:440–456.

11. Poolsup N, Suksumboon N, Kyaw AM. Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr 2013;5:39.

12. Szypowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. Eur J Endocrinol 2012;166:567–574.

13. Chetty VT, Almulla A, Oduyeungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (Hba1c) levels in Type 1 diabetic patients: a systematic review. Diabetes Res Clin Pract 2008;81:79–87.

14. Jacobs B, Phan K, Bertheau L, Dogbey G, Schwartz F, Shubrook J. Continuous glucose monitoring system in a rural intensive care unit: a pilot study evaluating accuracy and acceptance. J Diabetes Sci Technol 2010;4:636–644.

15. McGarraugh GV, Clarke WL, Kovatchev BP. Comparison of the clinical information provided by the FreeStyle Navigator continuous interstitial glucose monitor versus traditional blood glucose readings. Diabetes Technol Ther 2010;12:365–371.

16. Mazze RS, Strock E, Borgman S, Wesley D, Stout P, Racchini J. Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): Is CGM ready for real time? Diabetes Technol Ther 2009;11:11–18.

17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.

18. DCCT Study Group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.

19. WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization (2011).

20. American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care 2007;30 Suppl 1:S4–S41.

21. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999;16:716–730.

22. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711–1721.

23. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the Relationship Between Plasma Glucose and HbA1c. Diabetes Care 2002;25:275–278.

24. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther 2007;9:203–210.

25. Danne T, de Valk HW, Kracht T, Walte K, Geldmacher R, Söltler L, et al. Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia 2009;52:1496–1503.

26. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730–2732.

27. Carlson AL, Mullen DM, Bergenstal RM. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther 2017;19(S2):S4-S11.

28. Djakouré-Platonoff C, Radermercker R, Reach G, Slama G, Selam JI. Accuracy of continuous glucose monitoring system in inpatient and outpatient conditions. Diabetes Metab 2003;29 (2 Pt 1):159–162.

29. Clarke WL, Anderson S, Farhy L, Breton M, Gonder-Frederick L, Cox D, et al. Evaluating the clinical accuracy of two continuous glucose sensors using continuous glucose-error grid analysis. Diabetes Care 2005;28:2412–2417.
30. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007;50:2239–2244.
31. Baek YH, Jin HY, Lee KA, Kang SM, Kim WJ, Kim MG, et al. The Correlation and Accuracy of Glucose Levels between Interstitial Fluid and Venous Plasma by Continuous Glucose Monitoring System. Korean Diabetes J 2010;34:350–358.
32. Scu C. Interstitium versus Blood Equilibrium in Glucose Concentration and its Impact on Subcutaneous Continuous Glucose Monitoring Systems. Eur Endocrinol 2014;10:36-42.
33. Sharp P, Rainbow S. Continuous glucose monitoring and haemoglobin A(1c). Ann Clin Biochem 2002;39:516–517.
34. Salardi S, Zucchin S, Santoni R, Ragni L, Gualandi S, Cicognani A, et al. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA(1c) in pediatric type 1 diabetic patients. Diabetes Care 2002;25:1840-1844.
35. Ceriello A, Ihnat MA. ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 2010;27:862–867.
36. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1–7.
37. Hajime M, Okada Y, Mori H, Otsuka T, Kawaguchi M, Miyazaki M, et al. Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring. J Diabetes Investig 2018;9:75–82.
38. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 2004;27:931–935.
39. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta 1997;260:49–64.

Tables

Table 1. Baseline characteristics of study participants

|                      | All (n=82) | Type 1 DM (n=23) | Type 2 DM (n=59) |
|----------------------|------------|------------------|------------------|
| Age (years)          | 60±16      | 46±17*           | 65±12            |
| Sex (% women)        | 44 (54)    | 11 (48)          | 33 (56)          |
| Body weight (kg)     | 65.5±12.3  | 66.6±15.1        | 65.1±11.1        |
| Body height (m)      | 1.62±0.09  | 1.65±0.07*       | 1.60±0.09        |
| BMI (kg/m²)          | 25±4       | 24±4             | 25±3             |
| HbA1c (%)            | 8.3±1.4    | 8.3±1.7          | 8.3±1.3          |
| Mean glucose level (mg/dL) | 156.6±36.6 | 152.2±27.1       | 158.3±40.1       |
| / SD (mg/dL)         | 44.3±16.6  | 55.1±18.1*       | 39.6±13.6        |
| MAGE (mg/dL)         | 117.7±34.0 | 135.4±31.8*      | 110.2±32.3       |
| CONGA-1 (mg/dL)      | 29.9±9.1   | 35.4±8.1*        | 27.6±8.5         |
| %CV                  | 28.5±9.6   | 35.2±10.2*       | 25.6±7.7         |

DM: diabetes mellitus; HbA1c: hemoglobin A1c; SD: standard deviation; MAGE: mean amplitude of glucose excursion; CONGA: Continuous overlapping net glycemic action (1h intervals); %CV: percentage coefficient of variation; Data are mean±SD; * means type 1 DM versus type 2 DM; P<0.05

Table 2. Correlation of HbA1c with mean continuous glucose level
|                         | After 1 month (n=25) | After 2 month (n=34) | After 3 month (n=36) | Before 1 month (n= 55) | Before 2 month (n= 31) | Before 3 month (n= 36) |
|-------------------------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|
| Total glucose           | 0.69*                 | 0.39*                 | 0.16                  | 0.35*                  | 0.26                   | 0.42*                  |
| Highest 10% glucose     | 0.72*                 | 0.13                  | 0.19                  | 0.22                   | 0.18                   | 0.31                   |
| Highest 25% glucose     | 0.74*                 | 0.16                  | 0.20                  | 0.25                   | 0.14                   | 0.33                   |
| Highest 50% glucose     | 0.73*                 | 0.25                  | 0.19                  | 0.28                   | 0.16                   | 0.37*                  |
| Diurnal glucose         | 0.73*                 | 0.28                  | 0.08                  | 0.28*                  | 0.36*                  | 0.30                   |
| Nocturnal glucose       | 0.53*                 | 0.49*                 | 0.21                  | 0.35*                  | 0.04                   | 0.45*                  |

HbA1c: hemoglobin A1c; * means P<0.05

Table 3. HbA1c and glycemic variations in type 1 and type 2 DM patient
|                      | Total DM patient |                      |                      |                      |                      |                      |
|----------------------|------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                      | After 1 month    | After 2 month        | After 3 month        | Before 1 month       | Before 2 month       | Before 3 month       |
|                      | (n=25)           | (n=34)               | (n=36)               | (n= 55)             | (n= 31)             | (n= 36)             |
| HbA1c                | 8.1±1.4          | 8.4±1.4              | 7.6±1.2              | 8.5±1.2             | 8.2±1.2             | 8.2±1.5             |
| Mean glucose level   | 158.1±45.8       | 156.6±36.8           | 155.7±28.2           | 158.0±30.5          | 170.5±43.3          | 151.6±30.4          |
| SD (mg/dL)           | 39.1±11.1        | 43.9±17.7            | 45.1±15.7            | 43.1±13.4           | 45.8±19.4           | 43.9±13.6           |
| MAGE (mg/dL)         | 108.1±23.7       | 119.0±35.5           | 117.0±26.6           | 118.8±33.8          | 120.0±34.3          | 113.2±30.0          |
| CONGA-1 (mg/dL)      | 27.0±7.5         | 30.6±10.1            | 30.0±7.8             | 29.8±8.5            | 29.8±8.7            | 29.9±8.2            |
| %CV                  | 25.5±7.4         | 28.4±10.6            | 29.2±9.5             | 27.6±8.5            | 27.4±10.9           | 29.3±8.8            |

|                      | Type 1 DM patient |                      |                      |                      |                      |                      |
|                      | After 1 month     | After 2 month        | After 3 month        | Before 1 month       | Before 2 month       | Before 3 month       |
|                      | (n=7)             | (n=9)                | (n=11)               | (n= 13)             | (n= 10)             | (n= 10)             |
| HbA1c                | 7.7±1.0           | 8.6±1.2              | 8.1±1.2              | 8.5±1.1             | 8.0±1.5             | 9.0±1.8             |
| Mean glucose level   | 141.7±19.0        | 147.7±26.1           | 158.8±24.8           | 158.2±23.5          | 154.0±31.0          | 150.0±27.3          |
| SD (mg/dL)           | 41.9±10.0         | 56.4±17.9            | 56.6±16.4            | 55.0±11.2           | 57.5±25.4           | 49.5±12.7           |
| MAGE (mg/dL)         | 111.4±17.4        | 138.6±30.6           | 127.6±16.9           | 140.2±26.3          | 136.4±39.5          | 122.2±23.1          |
| CONGA-1 (mg/dL)      | 31.8±6.2          | 37.8±7.6             | 34.9±6.5             | 37.5±7.2            | 35.7±9.7            | 33.3±8.0            |
| %CV                  | 29.5±5.1          | 38.3±9.5             | 34.0±10.9            | 33.6±9.6            | 36.6±11.5           | 31.4±10.5           |

|                      | Type 2 DM patient |                      |                      |                      |                      |                      |
|                      | After 1 month     | After 2 month        | After 3 month        | Before 1 month       | Before 2 month       | Before 3 month       |
|                      | (n=18)            | (n=25)               | (n=25)               | (n= 42)             | (n= 21)             | (n= 26)             |
| HbA1c                | 8.3±1.5           | 8.4±1.5              | 7.4±1.2              | 8.4±1.2             | 8.2±1.0             | 7.9±1.2             |
| Mean glucose level   | 164.5±51.8        | 159.4±40.0           | 153.0±31.9           | 158.7±33.1          | 173.8±49.3          | 156.5±32.5          |
| SD (mg/dL)           | 37.7±11.9         | 39.6±15.9            | 40.7±13.7            | 39.7±12.6           | 39.8±49.3           | 42.9±14.3           |
| MAGE (mg/dL)         | 109.1±25.2        | 114.6±33.9           | 109.6±28.7           | 112.7±33.9          | 115.2±27.7          | 109.1±33.7          |
| CONGA-1 (mg/dL)      | 25.4±7.2          | 28.0±9.56            | 28.3±8.5             | 28.0±8.2            | 27.2±6.6            | 29.2±9.0            |
| %CV                  | 24.0±7.7          | 24.8±8.5             | 27.2±8.2             | 25.7±7.3            | 23.1±7.4            | 28.5±8.1            |

HbA1c: hemoglobin A1c; SD: standard deviation; %CV: percentage coefficient of variation; MAGE: mean amplitude of glucose excursion; CONGA: Continuous overlapping net glycemic action (1h intervals).

Table 4. Correlation between HbA1c and glycemic variations in type 1 and type 2 DM patient
| Total DM patient | After 1 month (n=25) | After 2 month (n=34) | After 3 month (n=36) | Before 1 month (n=55) | Before 2 month (n=31) | Before 3 month (n=36) |
|------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|-----------------------|
| Mean glucose level (mg/dL) | 0.69* | 0.39* | 0.16 | 0.35* | 0.26 | 0.42* |
| SD (mg/dL) | 0.49* | 0.20 | 0.17 | 0.01 | 0.15 | 0.06 |
| MAGE (mg/dL) | 0.46* | 0.06 | 0.30 | 0.18 | 0.17 | 0.17 |
| CONGA-1 (mg/dL) | 0.30 | 0.20 | 0.21 | 0.03 | 0.122 | 0.002 |
| %CV | 0.195 | 0.214 | 0.032 | 0.122 | 0.002 |

| Type 1 DM patient | After 1 month (n=7) | After 2 month (n=9) | After 3 month (n=11) | Before 1 month (n=13) | Before 2 month (n=10) | Before 3 month (n=10) |
|------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|-----------------------|
| Mean glucose level (mg/dL) | 0.56 | 0.12 | 0.26 | 0.07 | 0.16 | 0.07 |
| SD (mg/dL) | 0.59 | 0.52 | 0.15 | 0.48 | 0.32 | 0.35 |
| MAGE (mg/dL) | 0.65 | 0.14 | 0.14 | 0.09 | 0.01 | 0.12 |
| CONGA-1 (mg/dL) | 0.36 | 0.32 | 0.19 | 0.002 | 0.22 | 0.43 |
| %CV | 0.39 | 0.71* | 0.09 | 0.19 | 0.30 | 0.14 |

| Type 2 DM patient | After 1 month (n=18) | After 2 month (n=25) | After 3 month (n=25) | Before 1 month (n=42) | Before 2 month (n=21) | Before 3 month (n=26) |
|------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|-----------------------|
| Mean glucose level (mg/dL) | 0.70* | 0.45* | 0.08 | 0.32* | 0.38 | 0.57* |
| SD (mg/dL) | 0.52* | 0.18 | 0.18 | 0.07 | 0.16 | 0.11 |
| MAGE (mg/dL) | 0.47* | 0.06 | 0.17 | 0.26 | 0.27 | 0.25 |
| CONGA-1 (mg/dL) | 0.44 | 0.24 | 0.09 | 0.01 | 0.007 | 0.05 |
| %CV | 0.02 | 0.45* | 0.06 | 0.27 | 0.18 | 0.27 |

HbA1c: hemoglobin A1c; SD: standard deviation; %CV: percentage coefficient of variation; MAGE: mean amplitude of glucose excursion; CONGA: Continuous overlapping net glycemic action (1h intervals).